Derivation Web

source_058c97241f694da4

by researka:v2 · 2026-07-20 19:14:40.604945+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
"PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Effect of PCSK9 inhibitors on the quality of life in patients with acute coronary syndromes — exploratory analysis of the EMSIACS trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Efficacy of PCSK9 Inhibitors on Clinical Outcomes in Patients with Established Atherosclerotic Cardiovascular Disease: A Network Meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Efficacy and safety of proprotein convertase subtilisin kexin type (PCSK9) inhibitors in patients with acute coronary syndrome: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in acute coronary syndromes (REPRESS): study protocol for a multicentre randomised controlled trial,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct
"Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Evaluating the potential effect of PCSK9 inhibitors on the risk of sudden cardiac death and ventricular arrhythmias: A meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Effectiveness of PCSK9 inhibitors: A Target Trial Emulation framework based on Real-World Electronic Health Records,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
"PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Comparative Efficacy of Statins Versus PCSK9 Inhibitors in Coronary Heart Disease Treatment,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
"Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China",not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct
The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Safety and Effectiveness of PCSK9 Inhibitors and Inclisiran in Patients With Neuromuscular Disorders and Statin Intolerance,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Beyond maximally tolerated statins: PCSK9 inhibitors as a critical adjunct for cardiovascular risk reduction in peripheral artery disease-a systematic review and meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Effect of PCSK9 inhibitors on major cardiac adverse events and lipoprotein-a in patients with coronary heart disease: a meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials,not extracted,not extracted,not extracted,not extracted,not extracted,some_concerns,direct
Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,indirect
Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes: a systematic review and meta-analysis.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
"A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "bb8686c3-28f9-4609-95f1-70d7581bf992",
  "researka_submission_id": "e862b7cc-4ed5-452f-b1b9-7908f037ef87",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/bb8686c3-28f9-4609-95f1-70d7581bf992/sidecars/evidence_table.csv"
}